ALTERATIONS IN THE RENAL EXCRETION OF VALPROATE AND ITS METABOLITES AFTER CHRONIC TREATMENT

被引:20
作者
FISHER, JE
NAU, H
LOSCHER, W
机构
[1] SCH VET MED,DEPT PHARMACOL TOXICOL & PHARM,BUNTEWEG 17,W-3000 HANNOVER 71,GERMANY
[2] FREE UNIV BERLIN,INST TOXICOL & EMBRYOPHARMACOL,W-1000 BERLIN 33,GERMANY
关键词
ANTICONVULSANTS; VALPROATE; METABOLISM; URINARY EXCRETION; AUTOINDUCTION;
D O I
10.1111/j.1528-1157.1991.tb05627.x
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Urinary excretion of valproate (VPA, administered as its sodium salt) and its various metabolites was studied in rats before and after 6 weeks of chronic treatment with intraperitoneal (i.p.) injection of 200 mg/kg VPA three times daily. Urinary excretion was determined after i.p. injection of a single dose of 200 mg/kg VPA, to which [C-14]labeled VPA had been added to yield a dose of 1-mu-Ci/kg body weight. Unlabeled VPA and metabolites were determined in urine by gas chromatography-mass spectrometry (GC-MS). After injection of a single dose of VPA before onset of chronic treatment, approximately 40-50% of the dose administered was excreted in the urine within 24 h, mainly in the form of conjugated VPA and omega-oxidation products, i.e., 5-hydroxy-VPA and 2-propyl-glutaric acid. After chronic treatment, urinary excretion of total radioactivity increased approximately 75% as compared with activity before chronic treatment, demonstrating a marked increase in elimination rate of VPA during prolonged administration. Determination of VPA and metabolites in urine by GC-MS indicated that this enhanced elimination resulted mainly from increases in glucuronidation and beta-oxidation of VPA, whereas omega-oxidation was apparently not altered or was even reduced. The data strongly indicate that at least in rats VPA produces induction of its own metabolism during prolonged treatment.
引用
收藏
页码:146 / 150
页数:5
相关论文
共 29 条
[1]   VALPROIC ACID DOSAGE AND PLASMA-PROTEIN BINDING AND CLEARANCE [J].
BOWDLE, TA ;
PATEL, IH ;
LEVY, RH ;
WILENSKY, AJ .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1980, 28 (04) :486-492
[2]   CHRONIC SODIUM VALPROATE TREATMENT IN THE RAT - TOXICITY VERSUS PROTECTION AGAINST SEIZURES INDUCED BY INDOKLON [J].
CARL, GF ;
DELOACH, C ;
PATTERSON, J .
NEUROCHEMISTRY INTERNATIONAL, 1986, 8 (01) :41-45
[3]   SERUM CONCENTRATIONS AND ENZYME-INDUCTION IN EPILEPTIC CHILDREN TREATED WITH PHENYTOIN AND VALPROATE [J].
DEWOLFF, FA ;
PETERS, ACB ;
VANKEMPEN, GMJ .
NEUROPEDIATRICS, 1982, 13 (01) :10-13
[4]  
DICKINSON RG, 1979, J PHARMACOL EXP THER, V211, P583
[5]  
DICKINSON RG, IN PRESS THER DRUG M
[6]  
EYMARD P, 1971, J PHARMACOL-PARIS, V2, P359
[7]  
FURLANUT M, 1982, INT J CLIN PHARM RES, V2, P269
[8]   ASPECTS OF THE METABOLISM OF VALPROIC ACID [J].
GRANNEMAN, GR ;
WANG, SI ;
MACHINIST, JM ;
KESTERSON, JW .
XENOBIOTICA, 1984, 14 (05) :375-387
[9]   DISPOSITION OF VALPROIC ACID IN MAN [J].
GUGLER, R ;
SCHELL, A ;
EICHELBAUM, M ;
FROSCHER, W ;
SCHULZ, HU .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1977, 12 (02) :125-132
[10]  
JAGER E, 1980, EPILEPSIA, V21, P196